Comparison of the effects of amiodarone versus metoprolol on the frequency of ventricular arrhythmias and on mortality after acute myocardial infarction

https://doi.org/10.1016/0002-9149(93)90291-JGet rights and content

Abstract

A randomized trial was conducted to assess the efficacy of amiodarone versus metropolol or no antiarrhythmic treatment to suppress asymptomatic ectopic activity and improve survival in patients who have had myocardial infarction with a left ventricular ejection fraction of 20 to 45% and ≥3 ventricular premature complexes per hour (pairs or runs). Patients (n = 368) were randomly assigned to receive amiodarone 200 mg/day (n = 115) 10 to 60 days after the acute episode, and metoprolol 100 to 200 mg/day (n = 130) or no antiarrhythmic therapy (n = 123). After a median follow-up of 2.8 years, mortality in the amiodarone-treated patients (3.5 ± 2% SEM) did not differ significantly from that of untreated control subjects (7.7 ± 2.5%, p = 0.19), but was lower than that in the metoprolol group (15.4 ± 3.5%, p = 0.006). Patients treated with metoprolol had twice the mortality seen in control subjects, even though the differences were not statistically significant. Hotter studies performed at 1, 6 and 12 months showed that both amiodarone and metoprolol were equally effective in reducing heart rate, whereas only amiodarone significantly reduced ectopic activity (p < 0.0001). Thus, long-term treatment with amiodarone was clearly safe in patients with an ejection fraction of 20 to 45%, was effective in suppressing arrhythmias, and was associated with a tower mortality than metoprolol; corroboration is required in a larger trial.

References (27)

  • TR Vrobel et al.

    A general overview of amiodarone toxicity: its prevention, detection and management

    Prog Cardiovasc Dis

    (1989)
  • JT Bigger et al.

    The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction

    Circulation

    (1984)
  • CD Furberg

    Effect of antiarrhythmic drugs on mortality after myocardial infarction

    Am J Cardiol

    (1983)
  • Cited by (78)

    • Chronic Amiodarone Use and the Risk of Cancer: A Systematic Review and Meta-analysis

      2021, CJC Open
      Citation Excerpt :

      The authors of 10 studies responded, and the author of 1 trial19 provided unpublished cancer data, which we included in the analyses. Four authors who responded reported that they did not have access to the relevant data if it existed,20-23 and 6 authors responded that they did not collect data on cancer outcomes.24-29 Only 1 trial was at a low risk of bias in all domains (Fig. 2).17

    • Substrates and potential therapeutics of ventricular arrhythmias in heart failure

      2018, European Journal of Pharmacology
      Citation Excerpt :

      Amiodarone is a major antiarrhythmic drug in HF (Massie et al., 1996; Nul et al., 1997; Singh et al., 1995) when patients with HF are intolerant of β-adrenergic blockers. Clinical trials in patients with HF demonstrated that amiodarone significantly suppresses ventricular arrhythmias, and reduces mortality and sudden cardiac death without any adverse effects (Amiodarone trials Meta-analysis investigators, 1997; Ceremuzynski et al., 1992; Lo and Hsia, 2008; Navarro-Lopez et al., 1993; Santangeli et al., 2017). The therapeutic effect of amiodarone on ventricular arrhythmias in HF might be dependent on its multiple pharmacological actions, including the blockage of cardiac sodium, potassium, and calcium channels as well as sympatholytic effects (Ellison et al., 2003).

    • Ventricular Arrhythmias in Heart Failure Patients

      2008, Cardiology Clinics
      Citation Excerpt :

      Amiodarone does not appear to have any adverse effect on survival or heart failure. In the Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure, amiodarone had no significant impact on the incidence of SCD or on total mortality [96]; however, multiple smaller studies have shown significant mortality benefits and SCD reduction with the use of this drug [97–99]. Perhaps the largest of the amiodarone studies are the European Myocardial Infarct Amiodarone Trial and the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial, which focused on patients who had ischemic heart disease and prior myocardial infarction.

    • Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality

      2008, American Heart Journal
      Citation Excerpt :

      Among surviving patients who received amiodarone during days 17 to 45, the risk of all-cause and cardiovascular mortality during the follow-up period of 46 to 198 days was not significant. A total of 15 randomized clinical trials have evaluated the efficacy of amiodarone in reducing arrhythmias and all-cause or cardiovascular death.5-10,12,15-21 The 2 largest post-MI studies, EMIAT and CAMIAT, included 1486 and 1202 patients, respectively.

    View all citing articles on Scopus

    This study was supported in part by a research grant (1988–1990) from the Ramon Areces Foundation, Madrid, Spain.

    A list of the Spanish Study on Sudden Death (SSSD) investigators and participating institutions appears in the Appendix.

    View full text